Mineralys Therapeutics, Inc.
MLYS
$25.02
-$0.71-2.76%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 43.35% | 14.32% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -6.93% | -12.01% | |||
| Operating Income | 6.93% | 12.01% | |||
| Income Before Tax | 12.72% | 14.66% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 12.72% | 14.66% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 12.72% | 14.66% | |||
| EBIT | 6.93% | 12.01% | |||
| EBITDA | 6.93% | 12.01% | |||
| EPS Basic | 23.51% | 20.87% | |||
| Normalized Basic EPS | 23.52% | 20.86% | |||
| EPS Diluted | 23.51% | 20.87% | |||
| Normalized Diluted EPS | 23.52% | 20.86% | |||
| Average Basic Shares Outstanding | 14.10% | 7.86% | |||
| Average Diluted Shares Outstanding | 14.10% | 7.86% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||